| 摘要 |
The invention relates to a novel approach for the diagnosis and therapy of renal cell carcinoma, and other renal tumors, for example Wilms' tumor or other tumors not originating from the kidney or non-malignant kidney pathologies. The areas of application of the invention include the field of medicine and the pharmaceutical industry but also basic biology. The aim of the invention is to provide novel forms of treatment which are urgently required regarding the present state-of-the-art in treatment of renal carcinoma and other cancers. It was discovered that the Nbk protein which is highly expressed in normal renal tissue, is either not expressed at all or only weakly expressed in the tumor tissue. The protein expression and the loss of Nbk was examined in renal cell carcinoma samples by the use of immunohistochemistry, PCR strategies, mutation and deletion analyses. The inventive method for diagnosis is characterized by that the Nbk protein concentration or the Nbk RNA quantity or Nbk mutation or deletion or Nbk gene modification, preferentially methylation, in tissue-derived material is determined. The inventive agent for the therapy of the renal carcinoma and other cells with low Nbk protein or RNA expression is that Nbk expression is increased and directly initiates the therapeutic effect in these cells. The implementation of a novel agent in non-tumorous kidney diseases is based on the inhibition of Nbk RNA or protein expression or Nbk activity.
|
